Le Lézard
Classified in: Health, Science and technology
Subject: MAT

Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th


NAPLES, Fla., Nov. 29, 2021 /CNW/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.

Dr. Tucker's corporate presentation will be available on-demand starting at 7:00 a.m. ET. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric's management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at lk@hcwco.com, or KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

SOURCE Enveric Biosciences


These press releases may also interest you

at 17:13
The Center for Health Affairs is happy to announce the appointment of two new members to its Community Health Affairs Board of Directors. In addition, Susan Fuehrer, president of The MetroHealth System's Institute for H.O.P.E., has been named chair,...

at 17:13
Cate Osborn never dreamed before COVID hit that she'd be the creator of a thriving social media community of more than 2 million in just one year. Known as @catieosaurus online, Cate, who is a mental health advocate, full-time content creator, and...

at 17:00
Vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization (IVF), a new study has found. The findings, which were published in Obstetrics & Gynecology (the Green Journal), add to the growing body of...

at 17:00
Endo International plc will announce its fourth?quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S....

at 16:35
Incyte today announced updates regarding the clinical development of parsaclisib, the Company's next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K?), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a...

at 16:15
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, payable on March 31, 2022 to holders of record on March 10, 2022. The indicated annual dividend rate is $3.48 per share. ...



News published on 29 november 2021 at 07:30 and distributed by: